Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06502743
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-06-23
Brief Title:
First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab Followed by Maintenance Pembrolizumab With or Without Nesuparib in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient pMMR Endometrial Cancer
Sponsor:
Organization:
None
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
None
Enrollment Type:
None
Design Primary Purpose:
Design Masking:
Phases:
Observational Models:
Time Perspective List:
Who Masked List: